This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now?
by Zacks Equity Research
Hims & Hers and LifeMD are reshaping virtual care, but which one leads in earnings growth and platform scale? Let's dive in.
HIMSNegative Net Change LFMDNegative Net Change
medical medical-devices
Can Centene's Q3 Earnings Escape Industry's Cost Headwinds?
by Zacks Equity Research
CNC braces for Q3 results as revenue growth may be offset by rising medical costs and shrinking Medicaid memberships.
HUMPositive Net Change CNCNegative Net Change SEMNegative Net Change ERASPositive Net Change
earnings insurance medical
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
RDYNegative Net Change MRKPositive Net Change AMGNNegative Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
by Ahan Chakraborty
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
BMYNegative Net Change MRKPositive Net Change LLYPositive Net Change GILDNegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zacks Initiates Coverage of NAII With Neutral Recommendation
by Zacks Equity Research
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates CFFI as "Neutral." Explore how Natural Alternatives' expansion, innovation and prudent management balance growth potential with margin and execution challenges in a dynamic supplement market.
NAIIPositive Net Change
medical
Do Options Traders Know Something About ResMed Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
RMDNegative Net Change
medical medical-devices
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised
by Zacks Equity Research
Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.
BSXPositive Net Change HQYNegative Net Change RVTYNegative Net Change SOLVPositive Net Change
earnings medical medical-devices
Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings?
by Zacks Equity Research
GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.
BSXPositive Net Change ZBHPositive Net Change GEHCPositive Net Change SOLVPositive Net Change
medical medical-devices
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
by Sridatri Sarkar
TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.
GHNegative Net Change GEHCPositive Net Change TEMPositive Net Change
medical
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
BMYNegative Net Change PFEPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Cannabis Stock VFF Soars Over 300% YTD: Time to Buy, Sell or Hold?
by Sundeep Ganoria
Village Farms' surge reflects its pivot to a pure-play cannabis model, record profitability and a confident $10M share buyback.
TLRYNegative Net Change VFFNegative Net Change CURLFNegative Net Change
marijuana medical
Beat the Market the Zacks Way: PDD, Shopify, 3M in Focus
by Abhinab Dasgupta
Zacks showcases how its proven strategies and model portfolios continue to outperform, with PDD, Shopify and 3M among standout performers across portfolios.
UNHPositive Net Change MMMNegative Net Change MUPositive Net Change TMONegative Net Change LRCXPositive Net Change FICOPositive Net Change SBCFNegative Net Change NSSCPositive Net Change SHOPPositive Net Change PDDPositive Net Change CRDONegative Net Change
internet medical retail
CVS vs. FMS: Which Healthcare Services Stock Has More Upside?
by Moumi Mondal
CVS outpaces FMS in share gains and valuation appeal, with stronger earnings momentum and expanding health services driving its edge.
CVSPositive Net Change FMSNegative Net Change
medical medical-devices
ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Integer Holdings posts strong Q3 results with earnings and revenue beat, but shares plunge on a softer 2026 growth outlook.
PODDPositive Net Change PAHCNegative Net Change VCYTNegative Net Change ITGRNegative Net Change
earnings medical medical-devices
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
MASIPositive Net Change FMSNegative Net Change MMSIPositive Net Change WSTNegative Net Change
medical medical-devices
HCA Q3 Earnings Beat Estimates on Rising Inpatient Surgery Cases
by Zacks Equity Research
HCA Healthcare's Q3 earnings rise 42% y/y on stronger patient volumes and rising inpatient surgeries, prompting management to lift its 2025 outlook.
UHSPositive Net Change HCAPositive Net Change ANIPNegative Net Change EHCPositive Net Change
earnings finance medical
Community Health Q3 Earnings Beat on Rising Same-Store Admissions
by Zacks Equity Research
CYH's Q3 earnings surge on higher same-store admissions, cost cuts and a stronger payor mix, swinging to a $171M profit from a loss last year.
UHSPositive Net Change CYHPositive Net Change ANIPNegative Net Change EHCPositive Net Change
earnings finance medical
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
by Sundeep Ganoria
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
NVONegative Net Change LLYPositive Net Change GPCRPositive Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Amazon.com, Wells Fargo, Amgen, IDT and Village Super Market
by Zacks Equity Research
Zacks spotlights Amazon, Wells Fargo, Amgen, IDT and Village Super Market in its latest Analyst Blog, showcasing diverse growth drivers and risks.
AMZNPositive Net Change WFCPositive Net Change AMGNNegative Net Change IDTPositive Net Change VLGEANegative Net Change
finance medical retail utilities
Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs
by Aparajita Dutta
Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.
JNJNegative Net Change LLYPositive Net Change XLVPositive Net Change IYHPositive Net Change VHTPositive Net Change GEHCPositive Net Change
etfs medical
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
by Ekta Bagri
Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength
BMYNegative Net Change PFEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Best Momentum Stocks to Buy for Oct. 24
by Zacks Equity Research
ASM, IGC and RY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 24, 2025.
RYPositive Net Change IGCPositive Net Change ASMNegative Net Change
medical
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
NVSNegative Net Change LLYPositive Net Change INCYPositive Net Change EXASNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
by Zacks Equity Research
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
REGNPositive Net Change ALNYPositive Net Change NVSNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
UnitedHealth Recovers Its Rhythm Before Q3 Earnings: Time to Buy?
by Kaibalya Pravo Dey
UNH's Q3 results hinge on premium growth and Optum gains amid rising costs and margin pressure.
UNHPositive Net Change HUMPositive Net Change MOHNegative Net Change
earnings-outlook earnings-preview healthcare hmo insurance insurance-premium medical